They say nothing is certain in life except for death and taxes. At this point, we might add Obamacare lawsuits to that list.
Under new guidance from the Trump administration, one might expect for more states to seek Section 1332 Waivers to have more control over their ACA dollars. Yet in practice few states seem interested.
Join AEI and Health and Human Services Secretary Alex Azar for a discussion on the current initiatives to modernize health care regulation, expand consumer choice, and promote private-sector competition.
Health care played a peculiarly prominent role in the 2018 midterm elections: peculiar because the significance of its prominence, which is hard to parse, has tended to mislead both Democrats and Republicans.
Join AEI and Centers for Medicare and Medicaid Services Administrator Seema Verma for a discussion on Medicare’s movement toward value-based payment, as well as other potential reforms.
Sen. John McCain contributed to the Republican failure to repeal and replace the Affordable Care Act, but he was a minor player in the overall story.
Scientists have learned how cancer tricks the immune system—opening up new possibilities for research and, crucially, for treatment. David A. Shaywitz reviews “The Breakthrough” by Charles Graeber and “The Beautiful Cure” by Daniel M. Davis.
Both physicians and drug developers draw much of their authority from their ability to leverage mechanistic understanding to move from observation to insight. This ability is likely both better and worse than we typically recognize.
While all opioids pose some risk of dependence, the protections surrounding the new drug Dsuvia make it unlikely the drug will be diverted into the hands of abusers.
On this episode of the “AEI Events Podcast,” join us as we discuss the worsening shortage of primary care providers in the United States and how loosening state restrictions on nurse practitioners could save both money and lives.
When a poor nation becomes richer, its health care industry must function without donor support. But a shift from Western or Indian pharmaceutical companies to local producers can worsen patients’ health.